177 related articles for article (PubMed ID: 2133247)
1. Plasminogen activators and cancer.
Duffy MJ
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):681-7. PubMed ID: 2133247
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Schmitt M; Jänicke F; Graeff H
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
Reilly D; Andreasen PA; Duffy MJ
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998
[TBL] [Abstract][Full Text] [Related]
4. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
Duffy MJ
Biochem Soc Trans; 2002 Apr; 30(2):207-10. PubMed ID: 12023852
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-dependent cell surface proteolysis and cancer.
Blasi F; Verde P
Semin Cancer Biol; 1990 Apr; 1(2):117-26. PubMed ID: 2151734
[TBL] [Abstract][Full Text] [Related]
7. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
9. [Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
Halámková J; Kiss I; Tomášek J; Pavlovský Z; Tuček S; Penka M
Vnitr Lek; 2012 Feb; 58(2):129-34. PubMed ID: 22463093
[TBL] [Abstract][Full Text] [Related]
10. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
11. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
[TBL] [Abstract][Full Text] [Related]
12. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
Gandolfo GM; Conti L; Vercillo M
Anticancer Res; 1996; 16(4B):2155-9. PubMed ID: 8694536
[TBL] [Abstract][Full Text] [Related]
14. [Role of plasminogen activators in cancer dissemination. Clinical perspectives].
Alonso DF; Bal de Kier Joffé E
Medicina (B Aires); 1992; 52(3):252-6. PubMed ID: 1342692
[No Abstract] [Full Text] [Related]
15. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
17. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
[TBL] [Abstract][Full Text] [Related]
18. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
19. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
Harbeck N; Thomssen C
Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
[TBL] [Abstract][Full Text] [Related]
20. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
